TY - JOUR
T1 - (Chemo)Radiotherapy–Immunotherapy combinations
T2 - Time to get tailored?
AU - Mondini, Michele
AU - Deutsch, Eric
N1 - Publisher Copyright:
© 2021 American Association for Cancer Research.
PY - 2021/7/15
Y1 - 2021/7/15
N2 - Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification.
AB - Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification.
UR - http://www.scopus.com/inward/record.url?scp=85109112349&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-21-1173
DO - 10.1158/1078-0432.CCR-21-1173
M3 - Article
C2 - 33986023
AN - SCOPUS:85109112349
SN - 1078-0432
VL - 27
SP - 3815
EP - 3817
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 14
ER -